Asclepius

What Asclepius does

Asclepius Life Sciences Fund, L.P. is a private investment fund founded in 2016 and headquartered in New York that focuses on life sciences companies. The firm operates through three entities: the core Asclepius Life Sciences Fund, L.P., the Asclepius Master Fund, LTD for global investments, and Asclepius Investment Strategies, LLC as the dedicated management vehicle. The fund's offerings are restricted to accredited investors and distributed via a private offering memorandum, limiting the addressable investor base but providing a regulated distribution channel.

The business model follows standard private fund economics — generating revenue through management fees on assets under management plus carried interest on fund performance. The leadership team is the primary intellectual asset: Co-Founder & Managing Principal Steve Glover (30+ years of biopharma experience), Co-Founder & Principal Dr. Steven Gerst (medical/financial background), Steve Mackey as Managing Director of the Master Fund, and Yuri Maricich as Managing Director. KKR invested in 2021 (undisclosed amount), providing institutional validation.

Geographically, the core fund is U.S.-focused while the Master Fund vehicle provides global representation. The firm is small (1–10 employees) and operates without disclosed AI or technology-driven investment tooling, relying on the domain expertise of its principals for deal sourcing and portfolio management.

Name

Asclepius

Legal name

Asclepius Life Sciences Fund, L.P.

Website

https://asclepiuslifesciences.com/

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Asclepius is a New York–based private life sciences investment fund, founded in 2016, that invests in life sciences companies via accredited-investor-only vehicles and earns revenue through management fees and carried interest on its U.S. and global funds.

Ownership category

akta.pro rank

Product category

Life Sciences Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

Keywords

• Private equity fund
• Life sciences investment
• Venture capital
• Biotech investing
• Fund management

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Fund Management: Generates revenue through management fees and carried interest from the Asclepius Life Sciences Fund, L.P. The fund is only available to accredited investors via private offering memorandum.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Asclepius manages private investment funds focused exclusively on life sciences companies in the private market, primarily through Asclepius Life Sciences Fund, L.P. and Asclepius Master Fund, LTD. The funds pursue investment opportunities in healthcare, pharmaceuticals, biotechnology, biosciences, agriculture, and personal care, with concentration in rare diseases, immuno-oncology, inflammatory diseases, and medical devices. The firm exploits market inefficiencies through operational expertise, deep scientific insights, and financial analysis to deliver attractive risk-adjusted returns to its limited partner investors.

Product overview

Asclepius is a private equity investment fund focused on life sciences companies in private markets. The fund operates primarily through Asclepius Life Sciences Fund, L.P. and Asclepius Master Fund, LTD., targeting healthcare, pharmaceuticals, biotechnology, biosciences, agriculture, and personal care sectors. The fund concentrates on rare diseases, immuno-oncology, inflammatory diseases, and medical devices, leveraging operational expertise, deep scientific insights, and financial analysis to exploit market inefficiencies.

Differentiator

Problem solved

Functional benefit

Products and services

• Asclepius Life Sciences Fund, L.P. A private equity investment fund focused exclusively on life sciences companies in the private market, offered exclusively to accredited and qualified investors via private offering memorandum. The fund pursues opportunities across healthcare, pharmaceuticals, biotechnology, biosciences, agriculture, and personal care with concentration in rare diseases, immuno-oncology, inflammatory diseases, and medical devices.
• Asclepius Master Fund, LTD. A master fund structure used for global life sciences investments, represented by Steve Mackey as Managing Director. The Master Fund sits alongside the Asclepius Life Sciences Fund, L.P. as part of Asclepius's broader fund platform for accredited and qualified investors.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• OrbiMed Advisors: One of the largest healthcare-dedicated investment firms globally, investing across the life sciences and medical device continuum. Highly comparable to Asclepius given its focus on biopharma, medical devices, and healthcare with an operator-scientist model.
• RA Capital Management: Healthcare and life sciences-focused investment manager with both public and private strategies. Comparable to Asclepius in its concentrated focus on biopharma and life sciences investing, with deep scientific expertise.
• Baker Bros. Advisors: Biotech-focused investment adviser founded by scientific twins, investing across public and private life sciences. Directly comparable to Asclepius's life sciences focus with deep scientific credentials.
• Atlas Venture: Early-stage biotech venture firm focused on building life sciences companies. Comparable to Asclepius in therapeutic focus areas including immuno-oncology and rare diseases, with a scientist-led investment model.
• Deerfield Management: Healthcare-focused investment firm providing capital across stages to therapeutics, medical devices, and healthcare services. Comparable to Asclepius's broad life sciences mandate with operator support.
• Omega Funds: Life sciences-focused investment firm investing across private and public healthcare companies. Similar in scale and focus to Asclepius, with comparable therapeutic breadth across biopharma and medical devices.
• New Leaf Venture Partners: Healthcare and life sciences venture firm investing in development-stage biopharma and medical device companies. Comparable to Asclepius in therapeutic focus areas and private-market orientation.
• HBM Partners: Healthcare-focused investment manager with both private and public strategies. Directly comparable to Asclepius in its dedicated healthcare mandate and focus on growth-stage life sciences companies.
• Perceptive Advisors: Healthcare and biotechnology-focused investment firm managing both private and public strategies. Comparable to Asclepius in its deep sector specialization and life sciences investment focus.

Broad incumbents

• KKR Health Care Strategic Growth: KKR's healthcare-focused growth equity platform, also active in life sciences and an existing investor in Asclepius. Comparable as a broader incumbent player in healthcare PE with significantly greater scale and capital resources.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asclepius